Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Does a waist-worn ActiGraph accelerometer quantify community ambulation in persons with multiple sclerosis?
[New therapies in multiple sclerosis].
The invisible gorilla strikes again: sustained inattentional blindness in expert observers.
Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Alemtuzumab: The advantages and challenges of a novel therapy in MS.
Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
Personality traits of patients with multiple sclerosis and their relationship with clinical characteristics.
Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function.
The role of endogenous antiradical protective system in multiple sclerosis.
Treatment of resistant rheumatoid arthritis with minocycline: an open study.
Early detection of MS treatment complication may improve survival
Investigation of the relationship between vitamin D and bone mineral density in newly diagnosed multiple sclerosis.
Teaching NeuroImages: MRI time lag with acute disseminated encephalomyelitis.
Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study.
Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.
β-Lapachone ameliorization of experimental autoimmune encephalomyelitis.
Fenofibrate Inhibited the Differentiation of T Helper 17 Cells In Vitro.
Phenytoin: an old but effective antiarrhythmic agent for the suppression of ventricular tachycardia.
Gait variability and disability in multiple sclerosis.
Axonal Loss in a Rat Model of Optic Neuritis Is Closely Correlated with Visual Evoked Potential Amplitudes Using Electroencephalogram-based Scaling.
Minoderm
Cutting Edge: IL-6-Dependent Autoimmune Disease: Dendritic Cells as a Sufficient, but Transient, Source.
Neuromodulation of lower limb motor control in restorative neurology.
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.

Pages